MX2022011591A - Anticuerpos anti-ceramida. - Google Patents
Anticuerpos anti-ceramida.Info
- Publication number
- MX2022011591A MX2022011591A MX2022011591A MX2022011591A MX2022011591A MX 2022011591 A MX2022011591 A MX 2022011591A MX 2022011591 A MX2022011591 A MX 2022011591A MX 2022011591 A MX2022011591 A MX 2022011591A MX 2022011591 A MX2022011591 A MX 2022011591A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- ceramide
- binding fragments
- ceramide antibodies
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991232P | 2020-03-18 | 2020-03-18 | |
| PCT/US2021/022914 WO2021188770A1 (en) | 2020-03-18 | 2021-03-18 | Anti-ceramide antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011591A true MX2022011591A (es) | 2023-03-06 |
Family
ID=77771401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011591A MX2022011591A (es) | 2020-03-18 | 2021-03-18 | Anticuerpos anti-ceramida. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230167197A1 (enExample) |
| EP (1) | EP4121110A4 (enExample) |
| JP (1) | JP7809067B2 (enExample) |
| KR (1) | KR20230031814A (enExample) |
| CN (1) | CN115811987A (enExample) |
| AU (1) | AU2021236669A1 (enExample) |
| BR (1) | BR112022018682A2 (enExample) |
| CA (1) | CA3172201A1 (enExample) |
| IL (1) | IL296550A (enExample) |
| MX (1) | MX2022011591A (enExample) |
| WO (1) | WO2021188770A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016022883A1 (en) | 2014-08-07 | 2016-02-11 | Memorial Sloan-Kettering Cancer Center | Anti-ceramide antibodies |
| EP4308231A4 (en) * | 2021-03-16 | 2025-01-29 | Memorial Sloan Kettering Cancer Center | IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| EP0705344B8 (en) | 1993-06-24 | 2006-05-10 | Advec Inc. | Adenovirus vectors for gene therapy |
| AU687117B2 (en) | 1993-10-25 | 1998-02-19 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| EP2289550A3 (en) | 2000-01-27 | 2012-02-15 | MedImmune, LLC | Ultra high affinity neutralizing antibodies |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| EA201170357A1 (ru) * | 2008-08-20 | 2012-05-30 | Сентокор Орто Байотек Инк. | Инженерные антитела к il-13: композиции, способы и применение |
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| US9833949B2 (en) | 2011-08-29 | 2017-12-05 | Impossible Objects, Inc. | Apparatus for fabricating three-dimensional printed composites |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| WO2016022883A1 (en) | 2014-08-07 | 2016-02-11 | Memorial Sloan-Kettering Cancer Center | Anti-ceramide antibodies |
| TWI632160B (zh) * | 2015-01-16 | 2018-08-11 | 中央研究院 | 具有標的部分及效應部分的分子構建體 |
| CN118948892A (zh) * | 2017-05-01 | 2024-11-15 | 朱诺治疗学股份有限公司 | 细胞疗法与免疫调节化合物的组合 |
| WO2019237035A1 (en) * | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| US10975169B1 (en) * | 2019-09-27 | 2021-04-13 | Memorial Sloan Kettering Cancer Center | Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2 |
-
2021
- 2021-03-18 CN CN202180034154.0A patent/CN115811987A/zh active Pending
- 2021-03-18 IL IL296550A patent/IL296550A/en unknown
- 2021-03-18 KR KR1020227035522A patent/KR20230031814A/ko active Pending
- 2021-03-18 WO PCT/US2021/022914 patent/WO2021188770A1/en not_active Ceased
- 2021-03-18 JP JP2022556575A patent/JP7809067B2/ja active Active
- 2021-03-18 US US17/912,286 patent/US20230167197A1/en active Pending
- 2021-03-18 CA CA3172201A patent/CA3172201A1/en active Pending
- 2021-03-18 AU AU2021236669A patent/AU2021236669A1/en active Pending
- 2021-03-18 BR BR112022018682A patent/BR112022018682A2/pt unknown
- 2021-03-18 EP EP21771396.5A patent/EP4121110A4/en active Pending
- 2021-03-18 MX MX2022011591A patent/MX2022011591A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3172201A1 (en) | 2021-09-23 |
| CN115811987A (zh) | 2023-03-17 |
| EP4121110A1 (en) | 2023-01-25 |
| KR20230031814A (ko) | 2023-03-07 |
| AU2021236669A1 (en) | 2022-11-10 |
| WO2021188770A1 (en) | 2021-09-23 |
| JP2023534779A (ja) | 2023-08-14 |
| IL296550A (en) | 2022-11-01 |
| JP7809067B2 (ja) | 2026-01-30 |
| EP4121110A4 (en) | 2024-06-12 |
| BR112022018682A2 (pt) | 2023-02-14 |
| US20230167197A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002855A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno. | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
| PH12020552018A1 (en) | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies | |
| ES2523194T3 (es) | Anticuerpo monoclonal humano específico para cada tumor | |
| CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
| NI201700008A (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso. | |
| CR20230169A (es) | ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485) | |
| CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| EA201891066A1 (ru) | Антитела к ror1 | |
| ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
| ECSP088529A (es) | Anticuerpos anti mn y métodos para su utilización | |
| ECSP10010251A (es) | ANTICUERPOS MONOCLONALES QUE SE UNEN AL hGM-CSF Y COMPOSICIONES MÉDICAS QUE LOS COMPRENDEN | |
| CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| MX2019011520A (es) | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. | |
| ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| MX2018012473A (es) | Agentes que reconocen el epitopo de clever-1 y usos de los mismos. | |
| CO2018012497A2 (es) | Anticuerpos de interferón beta y usos de los mismos | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| MX2022011591A (es) | Anticuerpos anti-ceramida. | |
| MX2021015212A (es) | Anticuerpos antisortilina para uso en terapia. | |
| MX2024010955A (es) | Nuevos anticuerpos anti-cd3 y usos de los mismos |